Aiolos Bio Inc., a US-based biotech company, has officially launched with the successful completion of a Series A financing round, raising USD 245 million. The round was co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments, with additional participation from RA Capital Management.
Lead Candidate AIO-001
Aiolos Bio has disclosed its lead candidate, AIO-001, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody in-licensed from China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) under a deal signed in August 2023. While the specifics of the deal remain undisclosed, it is known that Hengrui retains the rights to develop the drug within the Greater China territory.
Potential and Applications of AIO-001
AIO-001 is anticipated to offer a significant treatment advantage with a potential twice-per-year dosage schedule, attributed to its potency and long half-life. The drug targets TSLP to address inflammation associated with severe asthma and is also being investigated for its applications in other immune conditions, including chronic obstructive pulmonary disorder (COPD) and chronic spontaneous urticaria (CSU).-Fineline Info & Tech
